High Clinical Longitudinality and Multi-Modal Real-world Data Solution

An Industry-leading Partnership for Hematologic Malignancies

NeoGenomics and ConcertAI are pleased to announce a transformation collaboration for Precision Hematology. Combining ConcertAI’s longitudinal clinical data with NeoGenomics comprehensive biomarkers derived from 100’s of hematological tests provides a defining solution to investigate real-world clinical practice and outcomes in hematological malignancies. The combination allows for real-world insights on more than 1M+ patient lives with hematologic malignancies, across 1,000+ oncology clinics, with high coverage of key biomarkers over the course of the entire patient treatment journey, and across multiple lines of therapy.

The Most Powerful Biomarker Data for Hematologic Malignancies Available

Linked to clinical records are cytogenetic and molecular biomarker data, presented with key dates and standardized, longitudinal laboratory test results across bone marrow and blood tests critical to hematologic malignancies (CBCs, Proteins, etc.). The largest and cleanest data available globally from an industry-leading team of bio-informaticists.

Directly analyze the raw data images and graphs (Morphology, Cytogenetics, Flow) and dive into the sequencer files (FASQ, VCF, BAM), especially created for researchers. Track the entire patient journey across multiple lines of therapy to derive unparalleled insights.

PRODUCTS

RW D 360™
Harmonized native structured EMR data with AI insights at a broad population level

- 200+ variables including:
  - Lab results (for diagnosis, stage, response)
  - Integrated Line of Therapy (Clans + EMR)
  - Diagnosis from EMR
  - Real-world overall survival
  - Procedures (Transplants, Transfusions, CAR-T)
  - ECOG
  - Confirmatory curation available

Patient360™
Expertly abstracted EHR data, via a patient level registry

- 100+ curated variables including:
  - Progression and response (incl. relapse, refractory) directly captured
  - Adverse events/toxicities (800+) linked to sentinel events
  - Risk Stratification Score
  - Longitudinal and genomic information from other labs

- ...plus all structured, native EMR, claims, and SDOH data

Compass360™
Comprehensive assessment for sample-to-diagnosis in a single report; with multi-modal testing:

- NGS
- Cytogenetics/Karyotyping
- FISH
- Flow
- PCR
- Morphology
- MRD

For Bone Marrow & Blood Samples
End User / Differentiated Use Case Examples

**Rigorous Standards for Real-World Evidence**

Our companies’ data are featured in hundreds of peer-reviewed publications and have been used as part of regulatory drug approvals. A wide variety of publications (page 3-4) span real-world endpoints like effectiveness, patient outcomes and quality of life, SDOH, adverse effects, healthcare resource utilization, mortality, and so much more.

ConcertAI has developed a highly validated approach to hematologic response information (PFS, relapse/refractory) via its Hem/Onc Center of Excellence. Real-world endpoints like Overall Survival leverage multi-modal composite mortality data from the EMR and third-party Obituary, SSDI, and Commercial Claims to ensure the highest levels of completeness critical for research. Ongoing FDA and FOCR real-world data collaborations generate foundational research and methodologies to advance RWE’s potential uses.²,³

ConcertAI and NeoGenomics research are driving progress in hematologic cancer treatments and improving patient outcomes with data that is guideline-driven and has provenance to the clinic bedside (ConcertAI) and the laboratory (NeoGenomics).

---

Highly Published: Select Real-World Data Publications from 2022-2023

AML:

CLL:
• Zakeri M, et. al; CO210 Real-World Effectiveness and Treatment Patterns of Venetoclax-Based Regimens Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in Community Settings. In: ISPOR, 2023 May 7-10. https://doi.org/10.1016/j.jval.2023.03.2435. Poster

Hodgkin Lymphoma:

MCL:

MDS:

Multiple Myeloma:

Pan-Heme:
2023 ASH Publications

NEOGENOMICS

AML
- Scarpa FJ, et. al; Mutation landscape of AML patients with compromised ASXL1-Cohesin interactions. In: ASH 2023, 2023 December 9-12. Poster

Myeloid
- Scarpa FJ, et. al; Molecular profiling of the RUNX1 RUNT domain in myeloid disorders. In: ASH 2023, 2023 December 9-12. Poster

MDS
- Dukenik D, et. al; Distinct SF3B1 Allele HEAT Repeat Location Is Associated with Co-Occurring Mutation Patterns in MDS. In: ASH 2023, 2023 December 9-12. Abstract

DLBCL

CONCERTAI

CLL

MM
- Radwanski K, et. al; Real-world evaluation of outcomes in relapsed/refractory multiple myeloma patients that are triple-class exposed after receiving 2 or more prior lines of therapy. In: ASH 2023, 2023 December 9-12. Poster

MDS

Contact us at ConcertAI or NeoGenomics to learn more